国产九价破冰,能否逆转HPV市场寒冬?

药事纵横
12 Jun

6月4日,中国首个国产九价HPV疫苗馨可宁9正式获批上市,打破了美国默沙东公司长达十余年的全球垄断,中国成为继美国之后,全球第二个具备独立自主供应高价次HPV疫苗能力的国家。但这一突破性进展的市场反响却不如想象中热烈,曾经“一苗难求”的盛况早已不再。行业巨头集体“雪崩”早在2024年,默沙东的HPV疫苗全球销售额达85.83亿美元,成为全球疫苗销售冠军,却出现了3%的同比下滑,而中国市场销售下降是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10